These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
876 related items for PubMed ID: 12465145
1. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. Sokka T, Pincus T. J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145 [Abstract] [Full Text] [Related]
6. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC. Scand J Rheumatol; 2009 Mar; 38(4):240-5. PubMed ID: 19229766 [Abstract] [Full Text] [Related]
7. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA. Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443 [Abstract] [Full Text] [Related]
8. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352 [Abstract] [Full Text] [Related]
11. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE. J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365 [Abstract] [Full Text] [Related]
12. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF. J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325 [Abstract] [Full Text] [Related]
13. The methotrexate therapeutic response in rheumatoid arthritis. Ortendahl M, Holmes T, Schettler JD, Fries JF. J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316 [Abstract] [Full Text] [Related]
14. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register. Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520 [Abstract] [Full Text] [Related]
15. Factors influencing length of time taking methotrexate in rheumatoid arthritis. Ortendahl M, Schettler JD, Fries JF. J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279 [Abstract] [Full Text] [Related]
16. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG. J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314 [Abstract] [Full Text] [Related]
17. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675 [Abstract] [Full Text] [Related]
18. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group. J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186 [Abstract] [Full Text] [Related]
19. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)]. Blanco FJ, Ballina J, Carbonell J, Martín-Mola E, Tornero J, Ramírez E, Galván J. Reumatol Clin; 2011 Apr; 7(2):88-93. PubMed ID: 21794790 [Abstract] [Full Text] [Related]
20. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Agarwal S, Zaman T, Handa R. Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623 [Abstract] [Full Text] [Related] Page: [Next] [New Search]